Business
CVRx announces availability of additional data supporting long-term benefits of Barostim
BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE
About this update from Cvrx, Inc.
[{"type":"text","content":"BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight long-term sustained benefits of Barostim in heart failure patients with reduced ejection fraction. “Publication of these data from the post-market phase of BeAT-HF in this prestigious peer-reviewed journal allows for more effective dissemination of the long-term results of this important trial and the positive symptomatic impact of Barostim on patients with heart failure,” said Kevin Hykes, President and CEO of CVRx. “Additionally, we are pleased at the favorable physician response to new abstracts released at THT in Boston on March 5, 2024, that show a reduction in additional heart failure interventions in patients with Barostim, as well as specific patient-centered benefits at long-term follow-up.” The manuscript is available online at the European Journal of Heart Failure website. CVRx previously announced some of these data as part of expanded labeling granted by FDA on December 23, 2023. The key benefits of Barostim contained in the manuscript include the following: There was not a statistically significant difference in the primary endpoint of CV death and HF hospitalization, demonstrating that the benefits of the therapy do not increase the long-term risk of harm to patientsPatients receiving Barostim + guideline-directed medical therapy (GDMT) had sustained and significant symptomatic improvements (6 minute hall walk, quality of life and NYHA class) at up to 2 years versus those patients receiving GDMT alonePatients receiving Barostim + GDMT had a 34% reduced likelihood of all-cause death or the need for left ventricular assist device (LVAD) implantation or heart transplant, suggesting a favorable effect of Barostim therapy Additionally, two new post-hoc analyses of the BeAT-HF trial data, presented on March 5, 2024 at Technology in Heart Failure Therapeutics (THT) 2024 in Boston, suggest additional important benefits of Barostim. Dr. William Abraham of the Ohio State Wexner Colle...